TNG Transgene SA

2024 Half-Year Financial Report

2024 Half-Year Financial Report

2024 Half Year Financial Report

Attachment



EN
24/09/2024

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Michael B. Schäfer
  • Michael B. Schäfer
TNG TRANSGENE SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
THEP THERMADOR HOLDING SA
FPE3 FUCHS PETROLUB SE
7h / 23m 7h / 23m 1 EN
Michael B. Schäfer
  • Michael B. Schäfer
TNG TRANSGENE SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
THEP THERMADOR HOLDING SA
FPE3 FUCHS PETROLUB SE
7h / 47m 7h / 47m 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
TNG TRANSGENE SA

Transgene : A dense clinical calendar in the coming weeks

>Financial visibility out to Q4 2025 confirmed - Transgène yesterday evening reported its H1 2024 results which contained no major surprises. Operating income totalled € 3.4m (vs € 4.8m in H1 2023). R&D costs were stable at € 15.4m and the net loss was € 16.5m (vs -€ 15.9m in H1 2023).Transgene's cash position reached € 15.3m, resulting in as expected financial visibility out to Q4 2025. This financial visibility is made possible by the fact that Transgene has al...

9h / 17m 9h / 17m 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
TNG TRANSGENE SA

Transgene : Un calendrier clinique chargé dans ces prochaines semaines

>Visibilité financière jusqu’au T4 2025 confirmée - Transgène publiait hier soir ses résultats financiers du S1 2024 qui se révèlent sans grande surprise. Les produits d’exploitations atteignent 3.4 M€ (vs 4.8 M€ au S1 2023). Les coûts de R&D sont stables à 15.4 M€ et la perte nette ressort à 16.5 M€ (vs -15.9 M€ au S1 2023).La position de trésorerie de Transgène atteint 15.3 M€ conduisant à avoir comme attendu une visibilité financière jusqu’au T4 2025. Cette vi...

9h / 35m 9h / 35m 1 FR
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene to Report Major Clinical Data before the end of 2024 – Confi...

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025 2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median 24-month follow-up data to be presented in Q4 2024 BT-001 (oncolytic virus): Data presented at ESMO (Sept. 2024) showed promising antitumor activity in solid tu...

23h / 32m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch